A framework followed by a clinical specification
Spain’s medicinal cannabis development has two concrete stages: Royal Decree 903/2025 established the regulatory framework, and the 2026 National Formulary monograph FN/2026/FMT/043 specifies a standardised THC/CBD oral solution. The monograph is published, rather than merely promised. Together the documents define a pharmaceutical pathway involving registered preparations, hospital specialists and hospital pharmacy services. They concern specified compounded medicines; they do not establish a general recreational market or turn associations into healthcare providers.
What the decree established
The decree of 7 October 2025 requires standardised preparations used in these formulas to be registered with AEMPS. Registration concerns their suitability as inputs for the specified medicines. Manufacturers must satisfy pharmaceutical quality requirements. A defined preparation is different from an unspecified plant product: the framework is designed around known composition, reproducibility and controlled manufacture. The distinction gives clinicians and pharmacists a consistent basis for treatment and monitoring, rather than asking a patient to interpret a commercial cannabis label.
Four refractory clinical areas
The 2026 monograph describes the oral solution as a last-line treatment when authorised, marketed industrial medicines do not satisfactorily treat the particular patient. It identifies refractory multiple-sclerosis spasticity, severe forms of epilepsy, chemotherapy-related nausea and vomiting, and chronic pain. These are clinical categories within the monograph, not a statement that every person with pain or nausea qualifies automatically. The prescribing decision still depends on the individual case and the treatment requirements established by the decree.
Who prescribes and who dispenses
Article 7 restricts prescribing to medical specialists within hospital care and requires the treatment rationale to be recorded in the clinical history. The patient must receive information about the available evidence, expected benefits and risks. Hospital pharmacy services prepare and dispense the formulas under articles 8 and 9 and work with the medical team on follow-up. This division makes responsibility explicit: the specialist makes and reviews the clinical decision; the pharmacy controls the preparation and pharmaceutical care.
Monitoring is part of the change
The decree requires periodic reassessment and consideration of stopping treatment when clinical benefit is insufficient or the benefit–risk balance becomes unfavourable. The monograph identifies adverse effects and interactions, including sedation and changes to the concentrations of other medicines. Healthcare professionals must report suspected adverse reactions to the pharmacovigilance system. The innovation is therefore not simply that cannabis appears in a prescription: it is a linked system of pharmaceutical quality, a defined clinical purpose and continuing evaluation.
What publication does and does not establish
The published monograph supplies the specification needed to implement the framework. It does not itself prove that every hospital already stocks a preparation or that every eligible patient has begun treatment. Those are implementation outcomes, distinct from the existence of the rules. The confirmed change is substantial nonetheless: Spain has moved from a decree setting conditions to a published National Formulary standard for a defined oral medicine, with clear professional responsibilities.
Sources & further reading
General information, not individual legal or medical advice.